Myostatin as a Biomarker for Diagnosis or Prognosis of Frailty and Sarcopenia: Current Knowledge

Affiliations

¹ Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain, haritz.arrieta@ehu.eus.
² Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain.

Comment

Haritz Arrieta et al. Gerontology. 2019.

. 2019;65(4):385-386.

doi: 10.1159/000496469. Epub 2019 Mar 1.

¹ Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain, haritz.arrieta@ehu.eus.
² Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain.

No abstract available

Comment on

Serum Myostatin Levels Are Higher in Fitter, More Active, and Non-Frail Long-Term Nursing Home Residents and Increase after a Physical Exercise Intervention.
Arrieta H, Hervás G, Rezola-Pardo C, Ruiz-Litago F, Iturburu M, Yanguas JJ, Gil SM, Rodriguez-Larrad A, Irazusta J. Arrieta H, et al. Gerontology. 2019;65(3):229-239. doi: 10.1159/000494137. Epub 2018 Nov 21. Gerontology. 2019. PMID: 30463070 Clinical Trial.
Myostatin: A Powerful Biomarker for Sarcopenia and Frailty?
Laurent MR, Dupont J, Dejaeger M, Gielen E. Laurent MR, et al. Gerontology. 2019;65(4):383-384. doi: 10.1159/000495839. Epub 2019 Mar 14. Gerontology. 2019. PMID: 30870838 No abstract available.